Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00331344 · ClinicalTrials.gov registry record · Phase 1

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

A Phase 1 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
100
Enrollment target
2
Study locations

NCT00331344 is a Phase 1 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 100 participants, below the 134-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (25% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00331344, a Phase 1 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
100 participants
Enrollment target
2
Study locations

Study Summary

This phase I/II trial is studying the side effects and best dose of ixabepilone and mitoxantrone hydrochloride when given together with prednisone and to see how well they work in treating patients with metastatic prostate cancer that did not respond to hormone therapy and chemotherapy. Drugs used in chemotherapy, such as ixabepilone, mitoxantrone hydrochloride, and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells

Conditions Studied

Recurrent Prostate Cancer Stage IV Prostate Cancer Adenocarcinoma of the Prostate

Interventions

  • DRUG prednisone
  • DRUG ixabepilone
  • DRUG mitoxantrone hydrochloride

Study Locations (2)

California

  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Wisconsin

  • University of Wisconsin Hospital and Clinics - Madison

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2006-04
Est. Completion 2010-11
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00331344

The ClinicalTrials.gov registry entry for NCT00331344 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (25% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which prednisone is the first listed.

NCT00331344 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT00331344 about?

NCT00331344 is a clinical study titled "Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy". This phase I/II trial is studying the side effects and best dose of ixabepilone and mitoxantrone hydrochloride when given together with prednisone and to see how well they work in treating patients with metastatic prostate cancer that did not respond to hormone therapy and chemotherapy. Drugs used i...

What is the current status of trial NCT00331344?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2006-04. Estimated completion is 2010-11.

What conditions does trial NCT00331344 study?

This clinical trial studies the following conditions: Recurrent Prostate Cancer, Stage IV Prostate Cancer, Adenocarcinoma of the Prostate.

What interventions are being tested in trial NCT00331344?

The interventions under investigation include: prednisone (DRUG), ixabepilone (DRUG), mitoxantrone hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00331344?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00331344 being conducted?

This trial has 2 study locations across California, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Prostate Cancer

All registered trials for this condition

Stage IV Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.